{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:10:14Z","timestamp":1789506614449,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","award":["NCT05343871"],"award-info":[{"award-number":["NCT05343871"]}],"id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128918","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:45:48Z","timestamp":1784670348000},"page":"128918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: A non-inferiority, randomized, double-blind, phase IV clinical trial in Pakistan"],"prefix":"10.1016","volume":"88","author":[{"given":"Huma Syed","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Tahir","family":"Yousafzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaid","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid Muhammad","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Irum Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Kehkashan Begum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Rabia Zuberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Farheen Aftab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wardah","family":"Mujahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Irfan Ghaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Afshan Piyarali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Miqdad Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Charu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Hedlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle Ivy","family":"Rosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Couvillion","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Scott","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Luby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Croda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise O.","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah Naz","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128918_bb0005","unstructured":"WHO. Director-General's statement on IHR Emergency Committee on Novel Coronavirus (2019-nCoV). 2020. https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov) (Accessed September 8th, 2024)."},{"issue":"4","key":"10.1016\/j.vaccine.2026.128918_bb0010","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1016\/S2214-109X(22)00075-4","article-title":"COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness","volume":"10","author":"Roozen","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2026.128918_bb0015","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128918_bb0020","unstructured":"WHO\/SAGE. Interim Statement on Dose-Sparing Strategies for COVID-19 Vaccines (Fractionated Vaccine Doses) 2021. https:\/\/www.who.int\/news\/item\/10-08-2021-interim-statement-on-dose-sparing-strategies-for-covid-19-vaccines-(fractionated-vaccine-doses) (Accessed September 8th, 2024)."},{"issue":"10269","key":"10.1016\/j.vaccine.2026.128918_bb0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(20)32520-4","article-title":"Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial","volume":"397","author":"Juan-Giner","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128918_bb0030","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S1473-3099(20)30693-9","article-title":"Fractional dose compared with standard dose inactivated poliovirus vaccine in children: a systematic review and meta-analysis","volume":"21","author":"Mashunye","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128918_bb0035","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1473-3099(22)00146-3","article-title":"COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID study","volume":"22","author":"Menni","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128918_bb0040","article-title":"Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial","volume":"42","author":"Batmunkh","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.vaccine.2026.128918_bb0045","doi-asserted-by":"crossref","unstructured":"Lazarus JV, Wyka K, White TM, et al. A survey of COVID-19 vaccine acceptance across 23 countries in 2022. Nat Med 2023 Feb;29(2):366\u2013375. doi:https:\/\/doi.org\/10.1038\/s41591-022-02185-4. Epub 2023 Jan 9. PMID: 36624316.","DOI":"10.1038\/s41591-022-02185-4"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128918_bb0050","article-title":"Willingness of the Jordanian population to receive a COVID-19 booster dose: a cross-sectional study","volume":"10","author":"Al-Qerem","year":"2022","journal-title":"Vaccines (Basel)."},{"issue":"8","key":"10.1016\/j.vaccine.2026.128918_bb0060","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116932119","article-title":"Testing fractional doses of COVID-19 vaccines","volume":"119","author":"Wi\u0119cek","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2026.128918_bb0085","series-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2024"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128918_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-005912","article-title":"Ethical and policy considerations for COVID-19 vaccination modalities: delayed second dose, fractional dose, mixed vaccines","volume":"6","author":"Wolff","year":"2021","journal-title":"BMJ Glob Health"},{"issue":"10269","key":"10.1016\/j.vaccine.2026.128918_bb0095","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128918_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.966416","article-title":"Half Dose ChAdOx Study Group. Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 vaccine: Viana project","volume":"13","author":"Valim","year":"2022","journal-title":"Front Immunol."},{"issue":"20","key":"10.1016\/j.vaccine.2026.128918_bb0105","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","article-title":"A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine","volume":"39","author":"Chu","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128918_bb0110","article-title":"Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil","volume":"44","author":"Moreira Puga","year":"2025","journal-title":"Lancet Reg Health Am"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128918_bb0115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00284-024-03689-7","article-title":"Homologous and heterologous Covid-19 booster vaccinations against SARS-CoV-2 infection in the elderly","volume":"81","author":"Acer","year":"2024","journal-title":"Curr Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128918_bb0120","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/resp.14191","article-title":"Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong","volume":"27","author":"Mok","year":"2022","journal-title":"Respirology"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128918_bb0125","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146316","article-title":"A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2","volume":"6","author":"Majdoubi","year":"2021","journal-title":"JCI Insight"},{"issue":"6522","key":"10.1016\/j.vaccine.2026.128918_bb0130","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.abe1107","article-title":"Preexisting and de novo humoral immunity to SARS-CoV-2 in humans","volume":"370","author":"Ng","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128918_bb0135","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ijid.2020.10.104","article-title":"High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa","volume":"102","author":"Tso","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128918_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02600-0","article-title":"Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis","volume":"20","author":"Yang","year":"2022","journal-title":"BMC Med"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128918_bb0145","article-title":"T-cell responses induced by an intradermal BNT162b2 mRNA vaccine booster following primary vaccination with inactivated SARS-CoV-2 vaccine","volume":"10","author":"Sophonmanee","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128918_bb0150","doi-asserted-by":"crossref","unstructured":"Hassan RT, Mohammed SH. Evaluation of immunoglobulin G level among subjects vaccinated with different types of COVID-19 vaccines in the Karbala population, Iraq. Biomed Biotechnol Res J 2022;6(3):466\u201371. doi:https:\/\/doi.org\/10.4103\/bbrj.bbrj_213_22.","DOI":"10.4103\/bbrj.bbrj_213_22"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128918_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001308","article-title":"Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial","volume":"2","author":"Pannus","year":"2022","journal-title":"PLoS Glob Public Health"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128918_bb0160","article-title":"Immunogenicity of a fractional dose of mRNA BNT162b2 COVID-19 vaccine for primary series and booster vaccination among healthy adolescents","volume":"10","author":"Puthanakit","year":"2022","journal-title":"Vaccines (Basel)."},{"issue":"1","key":"10.1016\/j.vaccine.2026.128918_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28169","article-title":"Antibody response 6 months after the booster dose of Pfizer in previous recipients of CoronaVac","volume":"95","author":"Silva","year":"2023","journal-title":"J Med Virol."},{"issue":"3","key":"10.1016\/j.vaccine.2026.128918_bb0170","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/jmv.27390","article-title":"The level of Ig anti-RBD SARS-CoV-2 after two doses of CoronaVac vaccine","volume":"94","author":"Ulhaq","year":"2022","journal-title":"J Med Virol."},{"issue":"5","key":"10.1016\/j.vaccine.2026.128918_bb0175","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1473-3099(22)00800-3","volume":"23","author":"Fadlyana","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128918_bb0180","series-title":"Immunogenicity and Reactogenicity of fractional vs. Full booster doses of COVID-19 vaccines: A non-inferiority, Randomized, Double-Blind, Phase IV Clinical Trial in Brazil","author":"Hedlin","year":"2024"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:31:52Z","timestamp":1789504312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26007279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S0264410X26007279"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128918","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: A non-inferiority, randomized, double-blind, phase IV clinical trial in Pakistan","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128918"}}